P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE. (23rd June 2022) - Martin, N.; Xu, A.; Stong, N.; Rytlewski, J.; Finney, O.; Campbell, T.; Pierceall, W.; Flynt, E.; Thompson, E.; Kaiser, S.